About Us

By combining deep expertise in peptide discovery and development, MBX Biosciences is pioneering a new era of peptide therapeutics that confront the challenges of managing endocrine diseases.

In overcoming the limitations of current therapies, we aim to improve the standard of care by reducing the severity of these diseases and simplifying the treatment regimen.

Core Values

The pillars of our organization

As both individuals and an organization, we are driven to make a positive impact in the world; that’s why we do what we do. Spanning hiring to company culture to product development, we are guided by our core values to help us reach our goals swiftly, responsibly, and efficiently.


Building trust through transparency and authenticity in all aspects of our work and communication.


Commitment to honesty and accountability. We act with the highest standards of professionalism and quality.


Embracing collaboration and inclusivity in all our work.


Translating leading-edge science into transformative medicines accessible to people in need of them.

Leadership team

MBX was founded by pioneers in the endocrine drug development field and is led by a team of seasoned industry veterans with a common goal to transform the treatment of endocrine disorders and improve people’s lives. Members of our leadership team have collaborated successfully over several decades on the discovery, development and commercialization of first-in-class endocrine therapeutics including Forteo®, Humalog®, and Byetta®.

Kent Hawryluk
President & CEO
Steven J. 
Prestrelski, PhD
Chief Scientific Officer
Richard Bartram, CPA
Chief Financial Officer
Michelle Graham
Chief Human Resources Officer
Michael A. Dorato, PhD, DABT, Fellow ATS, FRSB
Vice President, Pharmacology and Toxicology
Matt Gambino
Vice President, Marketing
Rita Shah, PharmD
Vice President, Global Regulatory Affairs
Paul Wright, PhD
Vice President CMC

Board of Directors

Tiba Aynechi, PhD
General Partner, Norwest Venture Partners
Jim Cornelius
Retired Chairman & CEO, Bristol Myers Squibb
Richard DiMarchi, PHD
Distinguished Professor, Indiana University
Carl Gordon
Managing Partner, Orbimed
Kent Hawryluk
President & CEO, Director of MBX Biosciences
Patrick Heron
Managing Partner, Frazier Healthcare Partners
Ed Mathers
General Partner, New Enterprise Associate
Ora Pescovitz
President, Oakland University

Scientific Advisory Board

John P. Bilezikian, MD

Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons Columbia University
Vice Chair of the Department of Medicine for International Education and Research Chief Emeritus of the Division of Endocrinology
Director of the Metabolic Bone Diseases Program at Columbia University Medical Center

David A. D’Alesio, MD

Professor of Medicine
Chief, Division of Endocrinology and Metabolism
Member of Duke Molecular Physiology Institute
Duke University School of Medicine

Kenneth Lim, MD, PhD, MPhil, FASN

Associate Professor of Medicine
Division of Nephrology and Hypertension
Indiana University School of Medicine

Mary Elizabeth Patti, MD

Investigator and Staff Physician, Joslin Diabetes Center
Director, Hypoglycemia Clinic
Co-Director, Molecular Phenotyping and Genotyping Core
Associate Professor of Medicine, Harvard Medical School